This Oncolytic Virus Therapies (OVTs)- Market Insight, Epidemiology and Market Forecast Forecast-2032 report delivers an in-depth understanding of the Oncolytic Virus Therapies (OVTs), historical and forecasted epidemiology as well as the Oncolytic Virus Therapies (OVTs) trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Oncolytic Virus Therapies (OVTs) market report provides emerging drugs, Oncolytic Virus Therapies (OVTs) market share of the individual cancer types, current and forecasted Oncolytic Virus Therapies (OVTs) market size from 2019 to 2032 segmented by seven major markets. The Report also covers current OVTs unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Oncolytic Virus Therapies (OVTs) Understanding and Treatment Algorithm
The publisher's Oncolytic Virus Therapies (OVTs) epidemiology report gives a thorough understanding of OVTs by including details such as overview of OVTs, advantages, disadvantages and available therapies. Comprehensive epidemiology insight of the tumors targeted by OVTs. Oncolytic viruses (OVs), considered an effective anticancer strategy in recent years, are a special type of virus that are naturally or genetically engineered and can replicate preferentially in tumor cells and inhibit tumor growth. OVT is a treatment using a virus that can replicate itself to kill cancer cells. Many species of viruses exist, but not all can be designed to be oncolytic viruses (OV). The typical features of these OVs must include being non-pathogenic, the ability to target and kill the cancer cells, and the capacity to be transformed to express tumor-killing factors through genetic engineering methods.
OVs have proven to be a powerful anticancer molecule, being able to be used for cancer diagnosis as well as treatment. Their multifunctional characteristics indicate good application prospects as cancer therapeutics, especially in combination with other therapies, such as radiotherapy, chemotherapy, and immunotherapy. Currently, only two oncolytic virus therapies are approved, namely, IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen) approved in the US and Europe in 2015, and DELYTACT (teserpaturev/G47∆; Daiichi Sankyo) approved in Japan in 2021.
Oncolytic Virus Therapies (OVTs) Epidemiology
The epidemiology section provides the insights about historical and current indication wise eligible patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Oncolytic Virus Therapies (OVTs) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In 2021, the total indication wise target patient pool cases across 7MM were about 632 K which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted intratumoral cancer therapies epidemiology [segmented as Total Incident cases of selected cancer types (Melanoma, Nonmelanoma skin cancer, Pancreatic Cancer, Renal cell carcinoma, Prostate Cancer, Brain Cancer, Bladder cancer, and Ovarian cancer), Target patient Pool of intratumoral therapies by Cancer Types and Treated cases by Cancer Types] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Oncolytic Virus Therapies (OVTs) Epidemiology
The epidemiology segment also provides the OVTs epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Drug Chapters
The drug chapter segment of the Oncolytic Virus Therapies (OVTs) report encloses the detailed analysis of OVTs marketed drugs and late stage (Phase III and Phase II) pipeline drugs. It also helps to understand the OVTs clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Emerging Drugs
The report provides the details of the emerging OVTs under the late and mid-stage of development for selected indications treatment.
Oncolytic Virus Therapies (OVTs) Market Outlook
The Oncolytic Virus Therapies (OVTs) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted OVTs market trends by analyzing the impact of current therapies on the market, unmet needs, and demand of better technology.
This segment gives a thorough detail of OVTs market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, the OVTs market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Findings
The OVTs market size in the 7MM is expected to change during the study period 2019-2032. The OVTs therapeutic market in the seven major markets is expected to increase during the study period (2019-2032). In 2021, the total market size of OVTs was approximately USD 122 million which is expected to rise during the study period (2019-2032).
The United States Market Outlook
The total market size of OVTs in the United States accounted for USD 84 million in 2021 which is expected to rise during the study period (2019-2032).
EU-5 Countries: Market Outlook
In EU5, the total market size of OVTs was about USD 38 million in 2021, which is expected to rise during the study period (2019-2032).
Japan Market Outlook
In Japan, the total market size of OVTs was USD 0.01 million in 2021, which is expected to rise during the study period (2019-2032).
Oncolytic Virus Therapies (OVTs) Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the OVTs market or expected to get launched in the market during the study period 2019-2032. The analysis covers Oncolytic Virus Therapies (OVTs) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Oncolytic Virus Therapies (OVTs) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses key players involved in developing OVTs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing patent details, and other information for emerging OVTs.
Reimbursement Scenario in Oncolytic Virus Therapies (OVTs)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL-Views
To keep up with current market trends, we take KOLs and SMEs ' opinions working in the OVTs domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or OVTs market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
The publisher performs Competitively and Market Intelligence analysis of the OVTs Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers a detailed overview of the development of OVTs across the several selected indications, explaining its various classes, benefits, and challenges for future
- Comprehensive insight has been provided into the OVTs epidemiology and treatment in the 7MM.
- Additionally, an all-inclusive account of both the current and emerging OVTs is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of OVTs market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global OVTs market.
Report Highlights
- In the coming years, OVTs market is set to change due to improved patient outcomes, treatment of cold tumors, rich emerging pipeline and convenient production and administration; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence OVTs R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for OVTs. Launch of emerging therapies, will significantly impact the OVTs market.
- This in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Oncolytic Virus Therapies (OVTs) Report Insights
- Patient Population
- Therapeutic Approaches
- Oncolytic Virus Therapies (OVTs) Pipeline Analysis
- Oncolytic Virus Therapies (OVTs) Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Oncolytic Virus Therapies (OVTs) Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Oncolytic Virus Therapies (OVTs) Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Oncolytic Virus Therapies (OVTs) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
Key Questions Answered
Market Insights:
- What was the OVTs Market share (%) distribution in 2019 and how it would look like in 2032?
- What would be the OVTs total market size as well as market size by therapies across the 7MM during the study period (2019-2032)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest OVTs market size during the study period (2019-2032)?
- At what CAGR, the OVTs market is expected to grow in the 7MM during the study period (2019-2032)?
- What would be the OVTs market outlook across the 7MM during the study period (2019-2032)?
- What would be the OVTs market growth till 2032 and what will be the resultant market size in the year 2032?
- OVTs patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
Epidemiology Insights:
- What is the challenges and unmet needs of the OVTs?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical OVTs patient pool in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
- What would be the forecasted patient pool of OVTs in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to OVTs?
- Out of all the 7MM countries, which country would have the highest incident population of Oncolytic Virus Therapies (OVTs) during the study period (2019-2032)?
- At what CAGR the population is expected to grow by 7MM during the study period (2019-2032)?
- What are the various recent and upcoming events which are expected to improve the uptake of Oncolytic Virus Therapies (OVTs)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the marketed OVTs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing OVTs for the treatment of selected cancers?
- How many OVTs are in-development by each company for selected cancer treatment?
- How many are emerging OVTs in mid-stage, and late stage of development for selected cancers treatment?
- What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the OVTs?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for OVTs and its status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging OVTs?
- What are the global historical and forecasted markets of OVTs?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the OVTs market
- To understand the future market competition in the OVTs market and Insightful review of the key unmet needs
- Organize sales and marketing efforts by identifying the best opportunities for OVTs in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the OVTs market
- To understand the future market competition in the OVTs market
Table of Contents
1. Key Insights2. Report Introduction
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Targovax
- Replimune
- Genelux Corporation
- Candel Therapeutics
- DNAtrix
- SillaJen
- Treovir
- Lokon Pharma AB
- Istari Oncology
- CG Oncology
- Amgen
- Daiichio Sankyo
